Image_5_The Circumferential Resection Margin Is a Prognostic Predictor in Colon Cancer.TIFF (1004.02 kB)

Image_5_The Circumferential Resection Margin Is a Prognostic Predictor in Colon Cancer.TIFF

Download (1004.02 kB)
figure
posted on 26.06.2020, 04:40 by Xin-Yi Tang, Meng-Xi Huang, Si-Qi Han, Yue Chang, Zhi-Ping Li, Xiao-Ming Kao, Yan-Yan Chen, Chao Liu, Ya-Di Huang, Yi-Tian Chen, Zeng-Jie Lei, Xiao-Yuan Chu

Objective: This study aimed to investigate the potential value of circumferential resection margin (CRM) in colon cancer prognostics.

Summary Background Data: CRM has been extensively studied as an important prognostic factor in rectal and esophageal cancer, but not in colon cancer.

Methods: Data from 6,681 CRM-positive patients and 25,908 CRM-negative patients diagnosed with colon cancer in 2010–2015 were obtained from the Surveillance, Epidemiology, and End Results database. Statistical analysis methods utilized included the chi-square test, Kaplan-Meier estimates, Cox proportional, and X-tile software analyses.

Results: After propensity score matching, CRM positivity was found to be negatively related with survival (P < 0.001). X-tile software identified 0 and 30 mm as optimal cutoff values (P < 0.001) for prognosis, which was applicable only in stage II–IV patients. A 20 and 33% risk decrease were observed in patients with CRM between 0 and 30 mm [95% confidence interval (CI) = 0.76–0.84], and larger than 30 mm (95% CI = 0.62–0.71), respectively. Chemotherapy strongly benefited prognosis with a hazard ratio of 0.36 (95% CI = 0.34–0.38) for overall survival (OS). Patients with a CRM value of 0–30 mm seemed to benefit most from chemotherapy compared with other groups. CRM and number of regional lymph nodes are independent risk factors, and the latter is a good substitute for CRM in AJCC stage I patients.

Conclusion: CRM positivity is a strong unfavorable survival indicator for colon cancer patients. A better outcome is expected with CRM values larger than 30 mm. This cutoff value only applied to stage II–IV patients. For stage I patients, number of regional lymph nodes is a good substitute to predict survival. Chemotherapy was another favorable prognostic factor, especially for patients with a CRM value between 0 and 30 mm.

History

Licence

Exports